Farglitazar
From Self-sufficiency
This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (February 2009) |
| File:Farglitazar.svg | |
| Systematic (IUPAC) name | |
|---|---|
|
N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine | |
| Identifiers | |
| CAS Number | 196808-45-4 |
| ATC code | none |
| PubChem | CID 170364 |
| Chemical data | |
| Formula | C34H30N2O5 |
| Molar mass | 546.612 g/mol[[Script error: No such module "String".]] |
Farglitazar is a is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.
Henke, Brad R.; Blanchard, Steven G.; Brackeen, Marcus F.; Brown, Kathleen K.; Cobb, Jeff E.; Collins, Jon L.; Harrington,, W. Wallace; Hashim, Mir A.; Hull-Ryde, Emily A. (1998). "N-(2-Benzoylphenyl)-l-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents". Journal of Medicinal Chemistry. 41 (25): 5020. doi:10.1021/jm9804127. PMID 9836620.
Categories:
- Pages with script errors
- Pages with broken file links
- Orphaned articles from February 2009
- Articles with invalid date parameter in template
- All orphaned articles
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
